Diagnosed with small cell lung cancer in July 2011, Barbara Bauer was a non-smoker and regular exercise enthusiast. Barbara believed she would beat lung cancer and used her skills as a public speaker to motivate people to exercise and remain positive during treatment. At Moffitt, Barbara participated in chemo, radiation and clinical trials but, sadly, lost her battle in 2012.
But before she passed away, Barbara became a passionate advocate for clinical trials and, like many others, knew that research was crucial to help others. Named in her honor, the Barbara Bauer Lung Cancer Innovative Research Grant fund was created to enable pilot projects that permit thoracic clinicians to develop new ideas in lung cancer including:
Developing novel approaches for prevention, early detection, and treatment of lung cancer.
Translating findings into new standards for personalized care with novel vaccines, lower dose radiotherapy, or new drugs.
Disseminating and increasing adoption of effective prevention and treatment interventions for lung cancer into clinical and public health practice.
Prelude to a Cure announces Dr. Theresa Boyle as the latest recipient of the Barbara Bauer Lung Cancer Innovative Research Grant.
With her primary interest in the interpretation of molecular results to facilitate the best therapy for patients, Dr. Boyle is also interested in precision-medicine translational research, using clinical trials to identify molecular changes in tumors for predicting response to specific therapies. Her research focus is on the development of lung cancer biomarker assays, including evaluation of cancer signaling pathways relative to drug response, for the development of assays such as the proximity ligation assay (PLA). Dr. Boyle also is interested in investigating biomarkers to identify patients who are most likely to respond to immunotherapy.
Named in honor of Barbara Bauer, a life-long non-smoker who passed away after a brief battle with small cell lung cancer, the Innovative Research Grant was created to fund pilot projects that lead to the prevention, early detection, and treatment of lung cancer. To make a contribution to help fund future lung cancer research projects call (813) 745-1713
Dr. Boyle’s winning abstract for the Barbara Bauer Lung Cancer Innovative Research Grant
Mass Spectrometry Analysis of Immune Checkpoint Proteins in Lung Cancer Abstract by Theresa Boyle, MD, PhD and John Koomen, PhD
The care of patients with lung cancer has improved significantly with the additional treatment option of immunotherapy. Approximately 20% of patients receiving immunotherapy have a dramatic response, and other patients have stable disease with an overall doubling in survival time. However, not all patients benefit and nothing clearly predicts who will or will not respond to immunotherapy. Many proteins have been identified which may play a role in how the immune system recognizes and fights against lung cancer cells. However, it is difficult to elucidate their interactive role with current clinical techniques because most methods assess only one protein at a time. Lung cancer specimens are often limited in quantity so there is a great need to develop methods that can analyze many proteins at one time in a single small sample. Proteomics, with the ability to simultaneously quantify multiple proteins in a tiny amount of tissue using similar techniques as those used to test for multiple performance enhancing drugs in athletes, is ideal for exploring the complex role and relationship of multiple proteins involved in lung cancer growth as well as the activation and deactivation of the immune system against lung cancer. Our immediate goal is to develop mass spectrometry methods to detect multiple proteins that may influence immunotherapy outcomes. Our ultimate goal is to apply mass spectrometry to guide both the use of currently available therapies and the development of new strategies for patients with lung cancer, enabling selection of the most effective regimen for each individual patient.
Prelude to a Cure announces Dr. Bradford Perez as the first recipient of Barbara Bauer Lung Cancer Innovative Research Grant
Prelude to a Cure, a non-profit organization founded to help fund lung cancer research, has announced that Dr. Bradford A. Perez has been named the recipient of its first Barbara Bauer Lung Cancer Innovative Research Grant. With a research project that evaluates the safety and efficacy of adding radiation therapy to immunotherapy in the treatment of lung cancer, Dr. Perez’s translational research was selected for its potential to guide combination therapy in human clinical studies.
“Prelude to a Cure was created to help fund cutting-edge research projects like the one proposed by Dr. Perez,” said Dr. Lary Robinson, founder of Prelude and one of Florida’s leading thoracic surgeons. “We can only defeat lung cancer by looking at it from different perspectives—and Dr. Perez proposed a novel research project that concerns the safety and effectiveness of combined therapies that can directly lead to improved patient outcomes.”
A Tampa native, Dr. Perez has worked at the National Cancer Institute in Bethesda, MD, and attended Duke University School of Medicine where he graduated in 2010. After completing his radiation therapy fellowship, he began working at Moffitt Cancer Center in July 2015 with a focus on both clinical and translational research in lung cancer in collaboration with Dr. Robinson and Prelude’s co-founder, Dr. Scott Antonia.
“I’m an early career investigator and a new faculty member at Moffitt,” said Dr. Perez. “By being selected for this incredible funding opportunity, Prelude is allowing me to obtain the preliminary data I need to apply for larger national grants. Those grants will allow us to gain a deeper level of understanding about how to more effectively treat lung cancer using combined radiation therapy and immunotherapy to activate the body’s own immune system and bolster the anti-tumor response.”
Named in honor of Barbara Bauer, a life-long non-smoker who passed away after a brief battle with small cell lung cancer, the Innovative Research Grant was created to fund pilot projects that lead to the prevention, early detection, and treatment of lung cancer. To make a contribution to help fund future lung cancer research projects call (813) 745-1713.
For more information email email@example.com